Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Medical Policy · Neurology, Pharmacy, Internal MedicineHigh impact

MA08.142f, Efgartigimod alfa-fcab (Vyvgart) and efgartigimod-alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)

Act
by Oct 26, 2026
Effective date
Oct 26, 2026
Identified
Jul 28, 2026

Summary

Independence Blue Cross Medicare Advantage policy MA08.142f adds new contraindication restrictions for efgartigimod alfa-fcab (Vyvgart) effective 10/26/2026, prohibiting concurrent use with FcRn blockers, complement inhibitors, immune globulin, and requiring neurologist involvement. The policy also removes the previous AChR antibody-positive requirement for gMG coverage. Billing teams must update prior authorization rules and clinical criteria checks before the October effective date.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Oct 26, 2026 · 7 steps
01Billing and prior authorization teams must update the authorization system for HCPCS codes J9332 and J9334 to.
02Reject claims if patient is concurrently receiving another FcRn blocker (Imaavy, Rystigo), complement inhibitor (Soliris, Ultomiris, Zilbrysq), or immune globulin (IVIG).
03Require documentation that patient is being treated by or in consultation with a neurologist.
04Remove the previous AChR antibody-positive requirement from clinical criteria.
05Update prior auth forms and decision trees accordingly.
06Educate providers and clinical staff on new contraindication restrictions.
07Claims submitted without neurologist consultation documentation or with documented concurrent prohibited medications will be denied.

Codes mentioned

J9332J9334

Original notice

MA08.142f, Efgartigimod alfa-fcab (Vyvgart) and efgartigimod-alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.142f, Efgartigimod alfa-fcab (Vyvgart) and efgartigimod-alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)MediumEffective Oct 26, 2026 · Medical PolicyMA08.142e, Efgartigimod alfa-fcab (Vyvgart) and efgartigimod-alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)MediumEffective Jan 1, 2026 · Medical Policy08.01.84f, Efgartigimod alfa - fcab (Vyvgart)MediumEffective Oct 26, 2026 · Medical Policy08.01.84f, Efgartigimod alfa - fcab (Vyvgart)MediumEffective Oct 26, 2026 · Medical PolicyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNeurologyPharmacyInternal MedicineCode J9332Code J9334

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account